BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20540350)

  • 41. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A; Stierle A; Anton R; Cazenave JP
    Biochem Pharmacol; 1982 Nov; 31(22):3597-600. PubMed ID: 6295405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vitamin E deficiency: its effect on platelet-vascular interaction in various pathologic states.
    Stuart MJ
    Ann N Y Acad Sci; 1982; 393():277-88. PubMed ID: 6756257
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparison of sympathomimetic amines with collagen, calcium ionophor and adenosine diphosphate in their effects on thromboxane formation of human platelet rich plasma.
    Ditter H; Matthias FR; Lasch HG
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):761-8. PubMed ID: 6083951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of platelet aggregation by novel benzoylpyrrole derivatives.
    Kurozumi S; Ohtsu A; Hoshina K; Jimba M; Komoriya K; Naruchi T; Wakabayashi T; Hashimoto Y; Ishimoto S
    Adv Prostaglandin Thromboxane Res; 1980; 6():305-7. PubMed ID: 7386272
    [No Abstract]   [Full Text] [Related]  

  • 45. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation.
    Smith JB; Araki H; Lefer AM
    Circulation; 1980 Dec; 62(6 Pt 2):V19-25. PubMed ID: 7002350
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ethanol-inhibited platelet prostaglandin synthesis in vitro.
    Stuart MJ
    J Stud Alcohol; 1979; 40(1):1-6. PubMed ID: 449324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Platelet prostacyclin binding in coronary artery disease.
    Jaschonek K; Karsch KR; Weisenberger H; Tidow S; Faul C; Renn W
    J Am Coll Cardiol; 1986 Aug; 8(2):259-66. PubMed ID: 3016061
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparative study of the inhibitory effect on platelet aggregation of various anti-inflammatory drugs].
    Migne J; Santonja R; Kunz S
    Therapie; 1973; 28(5):861-76. PubMed ID: 4368089
    [No Abstract]   [Full Text] [Related]  

  • 49. Biological actions of prostacyclin and its pharmacological use in platelet studies.
    Moncada S; Whittle BJ
    Adv Exp Med Biol; 1985; 192():337-58. PubMed ID: 3010671
    [No Abstract]   [Full Text] [Related]  

  • 50. Platelet aggregation independent of ADP release or prostaglandin synthesis in patients with hermansky-Pudlak syndrome.
    Rao GH; Gerrard JM; Witkop CJ; White JG
    Prostaglandins Med; 1981 Apr; 6(4):459-72. PubMed ID: 7280120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Some perspectives on platelets and prostaglandins.
    Willis AL; Smith JB
    Prog Lipid Res; 1981; 20():387-406. PubMed ID: 6804969
    [No Abstract]   [Full Text] [Related]  

  • 52. Prostaglandins, thromboxanes, and platelet function.
    Halushka PV; Knapp DR; Grimm L
    Curr Top Hematol; 1979; 2():75-143. PubMed ID: 233629
    [No Abstract]   [Full Text] [Related]  

  • 53. Malondialdehyde formation as an indicator of prostaglandin production by human platelets.
    Smith JB; Ingerman CM; Silver MJ
    J Lab Clin Med; 1976 Jul; 88(1):167-72. PubMed ID: 932533
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in platelet reactivity, prostacyclin and thromboxane production after long-term oral defibrotide in healthy and atherosclerotic rabbits.
    Löbel P; Palmér M; Schrör K
    Prog Clin Biol Res; 1987; 242():265-70. PubMed ID: 3313414
    [No Abstract]   [Full Text] [Related]  

  • 55. Platelet responsiveness and biosynthesis of thromboxane and prostacyclin in response to in vitro cocaine treatment.
    Togna G; Tempesta E; Togna AR; Dolci N; Cebo B; Caprino L
    Haemostasis; 1985; 15(2):100-7. PubMed ID: 3924789
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of atorvastatin on ADP-, arachidonic acid-, collagen-, and epinephrine-induced platelet aggregation.
    Zhao L; Liu D; Liu B; Hu H; Cui W
    J Int Med Res; 2017 Feb; 45(1):82-88. PubMed ID: 27913744
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is prostacyclin a physiologically important circulating anti-platelet agent?
    Steer ML; MacIntyre DE; Levine L; Salzman EW
    Nature; 1980 Jan; 283(5743):194-5. PubMed ID: 6243178
    [No Abstract]   [Full Text] [Related]  

  • 58. Coffee extracts inhibit platelet aggregation in vivo and in vitro.
    Bydlowski SP; Yunker RL; Rymaszewski Z; Subbiah MT
    Int J Vitam Nutr Res; 1987; 57(2):217-23. PubMed ID: 3115908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of circulating prostacyclin.
    Haslam RJ; McClenaghan MD
    Nature; 1981 Jul; 292(5821):364-6. PubMed ID: 7019720
    [No Abstract]   [Full Text] [Related]  

  • 60. Platelet function in the neonate.
    Stuart MJ
    Am J Pediatr Hematol Oncol; 1979; 1(3):227-34. PubMed ID: 543516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.